Morgan Stanley’s Cellectis CLLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $275K | Sell |
86,776
-400
| -0.5% | -$1.53K | ﹤0.01% | 5733 |
|
|
2025
Q4 | $422K | Sell |
87,176
-499
| -0.6% | -$2.08K | ﹤0.01% | 5592 |
|
|
2025
Q3 | $250K | Sell |
87,675
-5,120
| -6% | -$13.3K | ﹤0.01% | 5802 |
|
|
2025
Q2 | $142K | Buy |
92,795
+6,000
| +7% | +$8.67K | ﹤0.01% | 5994 |
|
|
2025
Q1 | $108K | Sell |
86,795
-111,899
| -56% | -$166K | ﹤0.01% | 5974 |
|
|
2024
Q4 | $358K | Buy |
198,694
+107,169
| +117% | +$200K | ﹤0.01% | 5559 |
|
|
2024
Q3 | $194K | Buy |
91,525
+5,200
| +6% | +$11.3K | ﹤0.01% | 5767 |
|
|
2024
Q2 | $161K | Buy |
86,325
+2,180
| +3% | +$5.72K | ﹤0.01% | 5762 |
|
|
2024
Q1 | $223K | Sell |
84,145
-68,305
| -45% | -$189K | ﹤0.01% | 5698 |
|
|
2023
Q4 | $470K | Buy |
152,450
+84,858
| +126% | +$201K | ﹤0.01% | 5639 |
|
|
2023
Q3 | $107K | Sell |
67,592
-9,560
| -12% | -$18.7K | ﹤0.01% | 5860 |
|
|
2023
Q2 | $152K | Sell |
77,152
-550
| -0.7% | -$1.05K | ﹤0.01% | 5763 |
|
|
2023
Q1 | $150K | Buy |
77,702
+3,561
| +5% | +$8.92K | ﹤0.01% | 5838 |
|
|
2022
Q4 | $156K | Sell |
74,141
-1,812
| -2% | -$4.11K | ﹤0.01% | 5770 |
|
|
2022
Q3 | $174K | Sell |
75,953
-23,998
| -24% | -$72.7K | ﹤0.01% | 5795 |
|
|
2022
Q2 | $283K | Buy |
99,951
+17,541
| +21% | +$61.8K | ﹤0.01% | 5713 |
|
|
2022
Q1 | $374K | Sell |
82,410
-37,557
| -31% | -$207K | ﹤0.01% | 5574 |
|
|
2021
Q4 | $974K | Sell |
119,967
-8,385
| -7% | -$82.4K | ﹤0.01% | 5087 |
|
|
2021
Q3 | $1.62M | Buy |
128,352
+13,492
| +12% | +$187K | ﹤0.01% | 4736 |
|
|
2021
Q2 | $1.78M | Sell |
114,860
-143,242
| -55% | -$2.41M | ﹤0.01% | 4723 |
|
|
2021
Q1 | $5.22M | Sell |
258,102
-48,622
| -16% | -$1.2M | ﹤0.01% | 3364 |
|
|
2020
Q4 | $8.3M | Sell |
306,724
-215,718
| -41% | -$4.84M | ﹤0.01% | 2714 |
|
|
2020
Q3 | $9.67M | Sell |
522,442
-277,194
| -35% | -$4.92M | ﹤0.01% | 2060 |
|
|
2020
Q2 | $14.2M | Buy |
799,636
+78,292
| +11% | +$1.19M | ﹤0.01% | 1669 |
|
|
2020
Q1 | $6.64M | Buy |
721,344
+7,318
| +1% | +$109K | ﹤0.01% | 2175 |
|
|
2019
Q4 | $12.2M | Buy |
714,026
+17,639
| +3% | +$236K | ﹤0.01% | 2188 |
|
|
2019
Q3 | $7.24M | Buy |
696,387
+201,612
| +41% | +$2.71M | ﹤0.01% | 2465 |
|
|
2019
Q2 | $7.72M | Buy |
494,775
+178,865
| +57% | +$3.19M | ﹤0.01% | 2444 |
|
|
2019
Q1 | $5.79M | Sell |
315,910
-19,510
| -6% | -$346K | ﹤0.01% | 2561 |
|
|
2018
Q4 | $5.58M | Sell |
335,420
-146,030
| -30% | -$3.39M | ﹤0.01% | 2770 |
|
|
2018
Q3 | $13.6M | Buy |
481,450
+96,847
| +25% | +$2.78M | ﹤0.01% | 2087 |
|
|
2018
Q2 | $10.9M | Buy |
384,603
+131,692
| +52% | +$3.92M | ﹤0.01% | 2290 |
|
|
2018
Q1 | $7.97M | Sell |
252,911
-243,366
| -49% | -$7.69M | ﹤0.01% | 2564 |
|
|
2017
Q4 | $14.5M | Buy |
496,277
+322,782
| +186% | +$8.79M | ﹤0.01% | 2010 |
|
|
2017
Q3 | $4.93M | Buy |
173,495
+100,706
| +138% | +$2.6M | ﹤0.01% | 2968 |
|
|
2017
Q2 | $1.88M | Buy |
72,789
+37,972
| +109% | +$906K | ﹤0.01% | 3858 |
|
|
2017
Q1 | $835K | Sell |
34,817
-35,240
| -50% | -$740K | ﹤0.01% | 4507 |
|
|
2016
Q4 | $1.19M | Buy |
70,057
+5,240
| +8% | +$96.8K | ﹤0.01% | 4336 |
|
|
2016
Q3 | $1.56M | Buy |
64,817
+59,104
| +1,035% | +$1.55M | ﹤0.01% | 3704 |
|
|
2016
Q2 | $152K | Buy |
5,713
+1,275
| +29% | +$37.4K | ﹤0.01% | 5059 |
|
|
2016
Q1 | $122K | Sell |
4,438
-275
| -6% | -$6.62K | ﹤0.01% | 5221 |
|
|
2015
Q4 | $146K | Sell |
4,713
-15
| -0.3% | -$455 | ﹤0.01% | 5225 |
|
|
2015
Q3 | $124K | Sell |
4,728
-6,906
| -59% | -$231K | ﹤0.01% | 5317 |
|
|
2015
Q2 | $419K | Buy |
11,634
+11,128
| +2,199% | +$391K | ﹤0.01% | 4834 |
|
|
2015
Q1 | $17K | Buy |
+506
| New | +$18.4K | ﹤0.01% | 6094 |
|
Other funds holding CLLS
BGI
LFCM
NAMI
Morgan Stanley's CLLS Position: Q1 2026 in Review
Morgan Stanley reduced its Cellectis (CLLS) stake by 0.46% in Q1 2026, selling an estimated $1.53K and leaving 86,776 shares worth $275K. The position accounts for ﹤0.01% of the portfolio, ranked #5733.
Morgan Stanley first reported a position in CLLS in Q1 2015 and has held it in 45 quarters since. The position peaked at $14.5M in Q4 2017. 32 funds tracked by Wall St. Rank hold CLLS as of Q1 2026.
- Morgan Stanley held 86,776 shares of Cellectis worth $275K as of Q1 2026.
- Morgan Stanley sold 400 Cellectis shares in Q1 2026, an estimated $1.53K.
- Cellectis made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #5733 holding.
- Morgan Stanley first reported a position in Cellectis in Q1 2015 and has held it in 45 quarters since.
- Morgan Stanley's Cellectis position peaked at $14.5M in Q4 2017.
- 32 funds tracked by Wall St. Rank held Cellectis as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.